|Articles|April 3, 2023
How to Meet the FDA’s Diversity Guidance
Author(s)Science 37
The pending FDA Guidelines is clear—pharma companies must improve diverse representation in clinical trials. In this whitepaper, Science 37 shares tips and strategies on how to achieve diversity in clinical trials.
Related Content
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation
3
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
4
ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots
5